Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Scalable expansion of human stem cell-derived islets for autologous transplantation in diabetes and use of 3-D bioprinted scaffolds
EF 2023-24
Résumé
Diabetes affects 530 million people globally and the incidence continues to rise. There are different subtypes of diabetes, but all are defined by a lack of insulin, rendering the body unable to regulate blood sugar levels. Fluctuating blood sugar levels can have severe consequences including kidney failure, vascular and heart disease, blindness, and early mortality. Injectable insulin remains the mainstay therapy, but it is imperfect, burdensome, and costly. We aim to develop a cure and revolutionize the treatment of diabetes.
The leading therapy aimed at curing diabetes has been the Edmonton Protocol of islet cell transplantation. Within this protocol, deceased donor islets are harvested and injected into the portal vein of a recipient with Type 1 Diabetes. While promising, it is limited by the need for life-long immunosuppression to prevent rejection of the graft as well as limited by the supply of donor islet cells. We propose using insulin-producing islet cells derived from human induced pluripotent stem cells (iPSCs) to treat diabetes.
These cells have been used to reverse diabetes in mouse models. We plan to generate these cells from patients with different forms of diabetes to generate a personalized medicine approach to treating diabetes. This method of auto transplantation eliminates the need for immunosuppression and mitigates the challenges encountered by the Edmonton Protocol. Our focus will be on safe scalable expansion of these cells and using 3D bio-printed scaffolds as an anchor. These scaffolds will optimize the implantation and incorporation of transplanted stem cell-derived islet cells. In parallel, we will continue work on encapsulating islet cells by packaging them in devices which can be implanted and removed with minimally invasive procedures.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506308
Name
Prus-Czarnecka Zofia
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Scalable expansion of human stem cell-derived islets for autologous transplantation in diabetes and use of 3-D bioprinted scaffolds
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune; Encapsulation; Immunosuppression; Insulin; Islet Cells; Pancreas; Personalized Medicine; Stem Cells; Transplantation; Type 1 Diabetes
Abstract
Diabetes affects 530 million people globally and the incidence continues to rise. There are different subtypes of diabetes, but all are defined by a lack of insulin, rendering the body unable to regulate blood sugar levels. Fluctuating blood sugar levels can have severe consequences including kidney failure, vascular and heart disease, blindness, and early mortality. Injectable insulin remains the mainstay therapy, but it is imperfect, burdensome, and costly. We aim to develop a cure and revolutionize the treatment of diabetes.
The leading therapy aimed at curing diabetes has been the Edmonton Protocol of islet cell transplantation. Within this protocol, deceased donor islets are harvested and injected into the portal vein of a recipient with Type 1 Diabetes. While promising, it is limited by the need for life-long immunosuppression to prevent rejection of the graft as well as limited by the supply of donor islet cells. We propose using insulin-producing islet cells derived from human induced pluripotent stem cells (iPSCs) to treat diabetes.
These cells have been used to reverse diabetes in mouse models. We plan to generate these cells from patients with different forms of diabetes to generate a personalized medicine approach to treating diabetes. This method of auto transplantation eliminates the need for immunosuppression and mitigates the challenges encountered by the Edmonton Protocol. Our focus will be on safe scalable expansion of these cells and using 3D bio-printed scaffolds as an anchor. These scaffolds will optimize the implantation and incorporation of transplanted stem cell-derived islet cells. In parallel, we will continue work on encapsulating islet cells by packaging them in devices which can be implanted and removed with minimally invasive procedures.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prus-Czarnecka, Zofia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~